The blood–brain barrier is a highly selective shield that protects the brain from harmful substances in the bloodstream.

The partnership will leverage SonoBiopsy tech for early detection of toxic amyloid abnormalities linked to Alzheimer’s.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Dementia remains one of the most pressing public health challenges of our time. Its economic burden exceeds $1 trillion ...

But the 72-year-old Mendoza, who has not been diagnosed with Alzheimer’s, isn’t getting the exam at a doctor’s office or a ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Yet despite decades of research, no treatment has been created that arrests Alzheimer’s cognitive deterioration, let alone ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and Parkinson’s disease, has increased as the population has aged. At the same time, ...

Lecanemab reduces toxic amyloid-β protofibrils, slowing Alzheimer’s disease progression and supporting personalised treatment ...

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...